In this context, we highlight microglial TREM2 and CSF1R as emerging targets for disease-modifying therapy in Alzheimer’s disease (AD) and other neurodegenerative disorders. The gene discussed is TREM2; the disease is early-onset autosomal dominant Alzheimer disease.